Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer
Дата публикации: 08-07-2026 07:07:00

Evidence for efficacy is based on the results from the POTOMAC study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
2EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
3EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
4EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
5EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
6New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
7Doctors just found a way to slow one of the deadliest prostate cancers7822-10-2025
8New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies5718-04-2024
9Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma0502-07-2026
10FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy 5701-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 5. Источник: www.esmo.org.